Fujifilm Plans to Invest $40M in New Facility
Source: sittithat tangwitthayaphum/Getty Images
January 11, 2021
Share
To support the growing viral vector sector, Fujifilm says it will invest $40 million in Fujifilm Diosynth Biotechnologies, a CDMO for biologics, viral vaccines, and viral vectors, to establish a new process development and manufacturing facility for viral vectors and advanced therapies.
The new facility, to be located in the greater Boston area, is scheduled to begin process development operations in fall 2021, and contract manufacturing services for early phase clinical trials by fall 2023.
“We are strategically establishing this facility in the greater Boston area where there is a high concentration of biopharmaceutical companies and academia innovating in the field of advanced therapies,” said Martin Meeson, CEO, Fujifilm Diosynth Biotechnologies.